Publication in the Journal PLOS ONE Examines the Role of the Stethoscope as a Vector for Nosocomial Pathogens and Multidrug-Resistant Bacteria in the Acute Care Setting

  • Study finds low levels of stethoscope hygiene education and practice and no significant reduction in stethoscope diaphragm contamination, including multidrug-resistant bacteria, after educational interventions
  • Authors call for elevation of stethoscope hygiene to that of the hands, establishment of practical and accurate hygiene guidelines, and evaluation of alternative options for stethoscope hygiene, including barriers
  • Findings add to the growing body of data highlighting longstanding stethoscope hygiene shortfalls and the resultant significant threat to patient health

April 26, 2021 San Diego CA – A new study in the journal PLOS ONE entitled “A quasi-experimental study on stethoscopes contamination with multidrug-resistant bacteria: Its role as a vehicle of transmission” found low levels of stethoscope hygiene education and practice among clinicians and no significant reduction in levels of stethoscope contamination, including nosocomial pathogens and multidrug-resistant (MDR) bacteria, despite educational intervention (consisting of flyers and 2 separate one-hour slide presentations).  

In this study involving 98 clinicians in a university-affiliated teaching hospital in Seoul, South Korea, self-reported stethoscope cleaning with alcohol swabs/gel or soap and water, increased after educational interventions for “every patient” from 10% to 20% and from 21% to 34% for “at least once per week,” while those reporting cleaning “on occasion” fell from 51% to 40.8% and “not at all” from 18% to 4.1%.  Despite the overall self-reported increase in hygiene practices, contamination rates of stethoscope diaphragms were not significantly reduced after the educational intervention as compared to baseline (97.9% vs. 91.5%, p=0.073) and there was no decrease in the contamination rate of MDR bacteria.  Additionally, in the post-educational study period, a shared stethoscope was found to be the vector in the infection of three patients with K. pneumoniae in the ward where the stethoscope was shared.

This timely study powerfully illustrates the need, as the authors conclude, for the healthcare community to elevate the practice of stethoscope hygiene to that of the hands,” said Dr. Frank Peacock, Chief Medical Officer at AseptiScope®.  “Current hygiene guidelines simply don’t consider the work pace in the real-world clinical settings and the ineffectiveness and inadequacies of today’s standards of care are painfully apparent.  The potential of a newer, workflow-compatible stethoscope hygiene intervention, The DiskCover System from AseptiScope, has been well-established and it holds the promise to become a new standard of care in the effort to protect patients from stethoscope-borne pathogens,” Dr. Peacock added.

The DiskCover System (www.diskcover.com), the flagship product from AseptiScope, Inc., is the first and only touch-free stethoscope barrier dispensing system.  The System dispenses single-use aseptic disk covers to protect patients from exposure to harmful pathogens and contaminants on the stethoscope diaphragm.  The compact System, designed to be mounted at the patient bedside, instantly applies individual disk covers, minimizing workflow disruption while encouraging clinician compliance.  

About AseptiScope, Inc.

AseptiScope is a privately funded San Diego, California based, clinical innovation company formed in 2016. The organization is founded and led by clinical innovation experts, leading medical researchers, and practicing physicians. The AseptiScope mission is to design, develop, manufacture and commercialize novel solutions that ensure “Infection Protection for Clinician & Patient.” The company is introducing the first true solution for the longstanding challenge of stethoscope contamination: The DiskCover System.  Visit www.diskcover.com for more information.

AseptiScope, Clean Cassette, and related logos are registered trademarks of AseptiScope, Inc.  DiskCover and related logos are trademarks of AseptiScope, Inc.

Media Contact, AseptiScope:
AseptiScope, Inc.
Irene Mulonni
irene@mulonni.com
858.859.7001

DOWNLOAD PDF

AseptiScope®, Inc. and Brookline Capital Markets Announce that AseptiScope has Exceeded its $5M Series A Target in Raise of $6 Million

  • The San Diego start-up is launching its flagship offering, The DiskCover™ System, the first and only touch-free system to address the longstanding challenge of stethoscope contamination
  • Proceeds will support the commercialization of The DiskCover System and development of new product offerings 

April 23, 2021 San Diego, CA – AseptiScope Inc., a privately funded San Diego, California based clinical innovation company and Brookline Capital Markets, a division of Arcadia Securities, LLC, a leading healthcare-focused investment banking boutique based in New York City, announced today that AseptiScope has exceeded its Series A $5M target in a raise of $6 million.  Brookline Capital Markets acted as exclusive placement agent for the financing round.

AseptiScope’s identification of a significant gap in infection control and their evidence-based approach in developing an attractive solution for it is a truly compelling story,” said Scott Katzmann, Managing Partner at Brookline Capital Markets.  “We are pleased to play a role in bringing AseptiScope’s high-consequence innovation to the marketplace,” he added.   

The COVID-19 pandemic has prompted an intense focus on infection prevention and infection control practices across the full spectrum of healthcare delivery.  In reality, healthcare associated infections are a longstanding challenge that take the lives of nearly 400,000 Americans annually in acute care and long-term care settings, and result in roughly $147 billion in direct and indirect costs.  

The stethoscope, the most frequently used medical instrument with over 5.5 billion annual auscultations in the USA alone, is commonly referred to as the “clinician’s third hand.”  It is a ubiquitous, valuable clinical tool and a symbol of the trust between healthcare providers and patients.  The stethoscope, however, is also a proven vector for disease transmission with CDC cleaning requirements that are incompatible with the intensity of stethoscope use and clinical workflow.  Recent studies reveal that stethoscopes are seldom cleaned between patients and, even when cleaning does occur, less than 4% of stethoscope diaphragms meet CDC hygiene requirements.

The DiskCover System (www.diskcover.com), the flagship product from AseptiScope, is the first and only touch-free stethoscope barrier dispensing system.  The System dispenses single-use aseptic disk covers to protect patients from exposure to harmful pathogens and contaminants on the stethoscope diaphragm.  The compact System, designed to be mounted at the patient bedside, instantly applies individual disk covers, minimizing workflow disruption while encouraging clinician compliance.  

From the outset we were impressed with the caliber of the Brookline team and their rapid embrace of the practical importance of our vision, months before the advent of COVID-19,” commented Scott Mader, AseptiScope founder and CEO.  “With their assistance, we are now well positioned to commercialize this important advance in infection control, The DiskCover System, while simultaneously investing in the future of AseptiScope,” he added.  

About AseptiScope, Inc.

AseptiScope is a privately funded San Diego, California based, clinical innovation company formed in 2016. The organization is founded and led by clinical innovation experts, leading medical researchers and practicing physicians. The AseptiScope mission is to design, develop, manufacture and commercialize novel solutions that ensure “Infection Protection for Clinician & Patient.” The company is introducing the first true solution for the longstanding challenge of stethoscope contamination: The DiskCover System.  Visit www.diskcover.com for more information.

AseptiScope, Clean Cassette, and related logos are registered trademarks of AseptiScope, Inc.  DiskCover and related logos are trademarks of AseptiScope, Inc.

About Brookline Capital Markets 

Brookline Capital Markets, a division of Arcadia Securities, LLC, is a leading healthcare-focused investment banking boutique based in New York City. Brookline provides a comprehensive suite of capital markets and strategic advisory services to cutting-edge public and private life sciences, medical technology, and diagnostics companies, as well as to Special Purpose Acquisition Companies (“SPACs”) and other emerging growth enterprises. 

Media Contact, AseptiScope:
AseptiScope Inc.
Irene Mulonni
irene@mulonni.com
858.859.7001

Media Contact, Brookline Capital Markets:
Michael D. Rhea
michael.rhea@brooklinecapmkts.com
646.807.4125

DOWNLOAD PDF